Trial Profile
A randomised phase II screening trial with functional imaging and patient reported toxicity sub-studies comparing Lapatinib plus capecitabine versus continued Trastuzumab plus capecitabine after local therapy in patients with ErbB2-positive metastatic breast cancer developing brain metastasis/es.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Oct 2022
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Capecitabine; Trastuzumab
- Indications Advanced breast cancer; Brain metastases
- Focus Therapeutic Use
- Acronyms LANTERN
- 29 Oct 2013 Accrual to date is 25% according to United Kingdom Clinical Research Network record.
- 17 Aug 2013 Accrual to date is 23% according to United Kingdom Clinical Research Network record.
- 12 Jul 2013 Accrual to date is 21% according to United Kingdom Clinical Research Network record.